Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Modern Chinese Medicine Group Co. Ltd. ( (HK:1643) ) has issued an update.
Modern Chinese Medicine Group Co., Ltd. has entered into a sale and purchase agreement to acquire a 30% stake in a target group for HK$41.82 million in cash, a price based on an independent valuation using a market approach. The deal qualifies as a major transaction under Hong Kong listing rules, triggering reporting, announcement, circular and shareholder approval requirements, though no physical general meeting will be held as controlling shareholder Modern Biotechnology Group Holdings Co., Ltd., which owns about 55.83% of the company, has provided written approval. A circular detailing the transaction is expected to be dispatched to shareholders by 9 February 2026, and completion remains conditional on due diligence and other precedent conditions, meaning the acquisition may or may not proceed; investors are urged to exercise caution when dealing in the shares.
The most recent analyst rating on (HK:1643) stock is a Hold with a HK$0.69 price target. To see the full list of analyst forecasts on Modern Chinese Medicine Group Co. Ltd. stock, see the HK:1643 Stock Forecast page.
More about Modern Chinese Medicine Group Co. Ltd.
Modern Chinese Medicine Group Co., Ltd., incorporated in the Cayman Islands and listed in Hong Kong, operates in the pharmaceutical and modern Chinese medicine sector, focusing on the development and commercialization of traditional Chinese medicine-related products and biotechnology-driven healthcare solutions.
Average Trading Volume: 475,305
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$496.8M
See more insights into 1643 stock on TipRanks’ Stock Analysis page.